Title of Invention

NEW BENZAMIDES AS PPARy MODULATORS

Abstract

The present invention relates to Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- and C-linked biradical selected from several possibilities; and -Z is a carbon radical selected from several possibilities. These compounds are PPAR[Upsilon] and PPAR[Upsilon]/ PPARdelta modulators and, therefore, are useful for the prophylactic and/or curative treatment of a condition or a disease mediated by these recetpcors.

Full Text

New benzamides as PPARy modulators The present invention relates to new benzamides acting as PPARy and PPARy /PPAR5 modulators, as well as to processes and intermediates useful for their preparation, and to pharmaceutical compositions containing them. BACKGROUND ART Peroxisome proliferator activated receptors (PPARs) belong to the superfamily of transcription factors known' as nuclear receptors. This family includes steroid, retinoid and thyroid hormone receptors. Three sub-types of PPARs have been identified in humans, rodents and Xenopus. They are PPARa, PPARp/8 and PPARy, each encoded by a different gene and showing different tissue distribution. The gene encoding for PPARy is transcribed in humans in three different mRNA isoforms (PPARyl, PPARy2 and PPARy3) through different splicing and promoter usage (Fajas et al., J Biol. Chem. 1997, 272, 18779-18789) . The PPARyl isoform shows a wide tissular distribution, while PPARy2 and PPARy3 are confined to certain tissues: PPARy2 is expressed only in adipose tissue and PPARy3 in adipose tissue as well as in macrophages (Fajas et al., FEBS Lett. 1998, 438, 55-60). Differences detected in tissue distribution as well as in the activation profile of the PPARy isoforms suggest they are involved in a variety of physiological functions playing a central role in homeostasis and lipid metabolism (Vamecq et al., Lancet 1999, 354, 141-148). These functions include, for example, lipidic transport in plasma and catabolism of fatty acids, regulation of insulin sensitivity and blood glucose levels, differentiation of macrophages that form atherosclerotic plaques, inflammatory response, carcinogenesis, hyperplasia, and adipocyte differentiation, the latter being the most verified function of the PPARy (Grimaldi, Prog. Lipid Res. 2001, 40, 269-281, Schiller et al., J. Biol. Chem. 2001, 276, 14133-14137) . Thus, the discovery of these transcription factors has provided new pharmacological targets for the development of useful therapeutic agents for the prevention and treatment of metabolic ' diseases such as diabetes, obesity and dyslipidaefnia. Non-insulin dependent diabetes mellitus (NIDDM) or type 2 diabetes is characterized by an insulin resistance in peripheral tissues, including muscle, liver, and adipose • tissue. Glitazones, selective PPARy agonist compounds, are drugs that reduce insulin resistance and lower blood glucose levels. Currently two products belonging to this family, rosiglitazone and pioglitazone, have been approved for the treatment of type 2 diabetes in humans. A great effort has been made in recent years to design new drugs that improve the side effect profile of the first glitazones, show a greater affinity as a PPARy ligands, and increase their potency in type 2 diabetes. This rational design has yielded structurally diverse compounds that show great potency and selectivity. Among them is interesting to highl ight the 2 - alkoxyphenylpropionic type derivatives ragaglitazar (1, EP 1049684) and tesaglitazar (2, EP 1084103) . These compounds are currently in phase III and II of clinical development, respectively. The use of compounds totally or partially blocking PPARy activity is useful for the inhibition of adipocyte differentiation, which constitutes an effective treatment for obesity. PPAR5 activation has been shown to lead to increased levels of HDL cholesterol in db/db mice (Leibowitz et al, FEBS Lett. 2000, 473, 333-336), and in diabetic-obese rhesus monkeys, while lowering the levels of LDL, triglycerides, and insulin (Oliver et al, Proc Nat Acad Sci USA, 2001, 98, 5306-5311) . The involvement of PPAR8 in fatty acid oxidation in muscles was further substained in PPARct knock-out mice (Muoio et al., J. Biol. Chem. 2002, 277, 26089-26097). A number of PPAR5 compounds have been reported to be useful in the treatment of hyperglycemia, hyperlipidemia and hypercholesterolemia (e.g. WO 02/59098, WO 01/603, WO 01/25181, WO 02/14291, WO 01/79197, WO 99/4815, WO 97/28149, WO 98/27974, WO 97/28115, WO 97/27857, WO 97/28137, WO 97/27847) . Taken together, these observations suggest that PPAR8 activation is useful in the treatment and prevention of cardiovascular diseases and conditions including atherosclerosis, hypertriglyceremia and mixed dyslipidemia (WO 01/00603) In vitro studies investigating the pharmacological modulation of PPAB.5 suggest that this kind of ligands may prove to be efficacious drugs for decreasing cardiovascular disease associated with metabolic syndrome, a condition comprised of a cluster of risk factors that also includes insulin resistance, obesity and hypertension (Mukjerheer, Drug News Perspect. 2002, 15, 261-267). Pro-differentiation and lipid accumulation effects have been reported in rodent and cultured human keratinocytes, as well as protection against cell death upon PPAR8 activation (Tan et al., Genes Dev. 2001, 15, 3263-3277; Schmuth et al., J. Invest. Dermatol. 2004, 122, 971-983). Modulators of these activities could be useful for treating a variety of skin disorders. In addition, PPAR5 has been implicated as a direct target in colorectal carcinogenesis in mice. All the evidences suggest that PPAR8 expression may promote tumour growth and, thus, may be also a potential target for the treatment of colorectal cancer (e.g. Park et al., Prod Nat Acad Sci USA, 2001, 98, 2598-2603). While PPARy is acknowledged as a master regulator of adipogenesis, PPAR8 may also play a role in adipocyte differentiation, as demonstrated by in vitro and in PPARS- deficient animals, promoting PPARy gene expression, which upon specific ligand activation promotes adipogenesis. Thus a non-selective PPARy/5 antagonist would be also a potential drug for obesity (Shearer et al., Curr. Med. Chem. 2003, 10, 267-280). This indicate that research for compounds displaying various degrees of PPARy and PPAR8 modulation should lead to the discovery of drugs that have great potential in the treatment of diseases such as type-2 diabetes, dyslipidemia, syndrome X, cardiovascular diseases (including atherosclerosis), hypercholesteremia, colon cancer, skin disorders (including psoriasis, and wound healing, Tan et a.1., Expert Opin. Ther. Targets, 2004, 8, 39) , and bone diseases (Pei et al.t J. Clin. Invest., 2004, 113, 805-806). Consequently, it is of great interest to provide new therapeutic agents that selectively modulate PPARy, and PPARy / PPARS. Kundu and collaborators have described benzamides/(3) , (4) and (5) as/w-D-glucosidase /inhibitors (Comb. JChem. High. 2002, 5,/545-550) . These compounds are structurally close to those/of this invent ioz^, but were described for different uses. Kundu and collaborators have described benzamides (3) , (4) and (5) as N-D-glucosidase inhibitors (Comb. Chem. High. 2002, 5, 545-550). WO 02/096426 disclose compounds (6) and (7) as intermediates for compounds which are matrix metalloproteinase inhibitors. Finally, WO 04/014844 disclose compounds (8) and (9) as factor IX modulators. These compounds are structurally close to those of this invention but were described for different uses. SUMMARY OF THE INVENTION One aspect of the present invention relates to the provision of new compounds of formula (I) , its stereoisomers and mixtures thereof, its polymorphs and mixtures thereof, and the pharmaceutically acceptable solvates and addition salts of all of them, wherein the central benzene ring may be substituted in me ta- or para-position and, -A is a radical selected froin the group consisting of -0R1, -NR20R1 and -NR2R3; wherein Rl, R2 and R3 independently represent -H or - (C1-C4) -alkyl; -W- is a biradical selected from the group: -NH-CH(E)-, - and -N(D) -CH2-GH2-; wherein E is a radical of the -G-I-J-K type and D is a radical of the -G-I'-J-K type where: C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several - OH or - F, and (C1 - C4) -alkoxyl optionally substituted by one or several -OH or -F; b) a five- or six-member ed aromatic heterocycle containing from one to three heteroatoms selected from 0, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (d-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, CONR2R3, {C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; c) benzene or benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) -alkylsulphenyl, (Cx-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02- , (QL-C*) -alkyl-S020- , -NR2R3, CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and d) a bicyclic system consisting of a benzene fused with a five- or six-member ed ring optionally containing from one to three heteroatoms selected from 0, S and N, this bicyclic system being optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHD, -SH, -N02, -CN, -F, -Cl, -Br, (CL-C4) -alkanoyl, (C1-C4) -alkaxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkyi sulphonyl, (C1-C4) -alkyloxy-SOa-, (C1-C4) -alkyl-S020-, -NR2R3, C0HR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxcyl optionally substituted by one or several -OH or -F; -J- is a bond or a biradical selected from the following groups: a) - (CH2) 1-4-alkylidene; b)-o-, and f c) -O- (C1-C4)^y^%^C1) -0-, S- (CX-CM) ■ -i (Ox GJ S^, , -SO- (C1-C4) -, . - (QL-G*) -SO-, -S02- (C1-C^r^^ (Cx-C4) -SOi- r -OCO- (C1-Cft) -, -COO- (Cx^ C4) -oco-, - (Cx-C4) -coo-, -oc£>ra^(C1-C4) -, NR2COO- (Cx-C4> -, - (Ca^£***6cOHR2-, - (C1-C4) -NR2COO-, -CONR2-(^^Tf-, -NR2CO- (C1-C4) -, - (Cx-C4)-CX)NI^-^^2HR2- (Cx-C4) -, -NR2S02- (Cx-CU) -, - >tgg^g -K is a; radical selected from the following groups: a) -H; b) (Cx-CU)-alkyl; c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CEO, -SH, -N02, -Off, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, {C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-SO2-, (Cx-C4) -alkyl-S020-, -NR2R3, -C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02/ -CN, -F, -CI, -Br, (C1- C4) - alkanoyl, (C1- C4) - alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (CL-C4) -alkylsulphonyl, (C1-C4) -alfcyloxy-S02-, (C;L-C4) -alkyl-S020- , -NR2R3, -C0NR2R3, (C1-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1- C4) - alkanoyl, (C1- C4) - alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (Cx-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (cL-C4) -alkyl-S020-, -NR2R3, -C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -P, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; -I' - is a biradical of a cycle selected from the following groups: a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene f all optionally substituted by one or several radicals independently selected from -OH, 0x6 (=0) , -CHO, -SH, -N02/ -CN, -F, -Cl, -Br, (C3.-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (QL-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; b) a five- or six-membered aromatic heterocycle containing frem one . to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02/ -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020- , -NR2R3, -COKR2R3, (C1.-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; c) benzene substituted by one or several radicals independently selected from - OH, - CHO, -SH, -NO2, -Of, ~F, -CI, -Br,. (C1-C4)-al3canoylf (C3.-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C3.-C4) -alkylsulphenyl, (C1-C4) -alkyloxy-SOa-, {C1-C4) -alkyl-SOsO-, -NR2R3, -C0NR2*3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C3.-C4) -alkoxyl optionally substituted by one or several -OH or -P; and d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing .f rom one to three heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkylcoxy-SO2-, (C1-C4) -alkyl-SQ20-, -NR2R3, -C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F, phenyl ,phenoxy and beuzyloxy; Z is a radical selected from the following groups: a) -Q-I-J-T wherein -Q- is a biradical -(CH2)1-3-; -I- is as defined above; -J- is as defined above; and -T is a radical selected from the following groups: r a-a) -H; a.b) (C1-C4)-alkyl; a.c)a radical from a cycle selected from the f ollowing: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C3.-C4) -alkyl optionally substituted by one or several -OH or -F, and {C1-C4) -aikoxyi optionally substituted by one or several -OH or -F; a. d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (QL-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1- C4) - alkyl sulphonyl, C1-C4) - alkyloxy-S02-, C1-C4)-alkyl-S020-, -NR2R3, -C0NR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; a.e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -CI, -Br, (QL-CJ -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) - alkanoyl oxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C3. - C4) - alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1.-C4) -alkyl optionally subs t i tut ed by one or several - OH or - F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and a. f) a radical from a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from 0, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, OXO (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (QL-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4)-r alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; b) - (CH2)S-X-P-I-J-T wherein s is 2 or 3; -X- is selected from the group consisting of -0-, -3-, -SO-, -S02- and -NR4-, being R4 a radical selected from the group: b.a) -H; b.b) (Cx-C1o)-alkyl; b, c) cycloalkyl, cycloalkyl-CO-, cycloalkyl- (C1-C3) -alkyl and cycloalkyl- (C1-C3) -alkanoyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=0), -CHO, -SH, -NO2, -CN, -F, -CI, -Br, (QL-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1 - C4) - alkyl sulphiny 1, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and - (C1-C4) -alkoxyl optionally substituted by one or several OH or F; b.d) phenyl, phenyl-CO-, phenyl- (C1-C3) -alkyl and phenyl- (C1.-C3) -alkanoyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -N02/ -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-CU) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1.-C4) -alkyl sulphonyl, {C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or'-F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and b. e) a heterocycle, heterocycle - CO, heterocycle- (C1-C3) -alkyl and heterocycle- (C1-C3) -alkanoyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1 - C4) - alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1 - C4) - alkyl sulphinyl, (C1 - C4) - alkyl sulphenyl, (C1 - C4) - alkyl sulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020- , -NR2R3 , -C0NR2R3 , (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4)-alkoxyl optionally substituted by one or several -OH or -F; -P- is a bond or a -(CH2)1-4- biradical; -I- is as defined above; -J- is as defined above; and -T is a radical as defined above; c) -(OT2)u-CO-HR5-P-I-J-T wherein u is 1 or 2; -R5 is a radical selected from the group: c.a) -H; c.b) (C1-C10)-alkyl; c.c) cycloalkyl and cycloalkyl- (C1-C3) -alkyl, wherein the cycloalkyl is a five- or six-member ed ring optionally substituted by one or several radicals- selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1 - C4) - alkoxycarbonyl, (C1-C4) - alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3 , (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4)-alkoxyl optionally substituted by one or several -OH or. -F; c. d) phenyl and phenyl - (Cx- C3) - alkyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -N02/ -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1 - C4) - alkyl sulphenyl, (C1- C4) - alkyl sulphonyl, (C1-C4) ~ alkyl oxy-S02-, (C1.-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally, substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and c.e) a heterocycle and heterocycle- (C1-C3) -alkyl, wherein the heterocycle is a five- or six-meiribered ring containing from one to three heteroatoms selected from O, S and N, being this heterocyclo optionally substituted by one or several radicals selected from -OH, oxo (==0) , -CHO, -SH, -NO2V -CHr -F, -CI, -Br, (C1-C4)-alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-r CU) - alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (tV-Cj -alkyl optionally substituted by one or several several -OH or - F, and (C1-CUJ-alkoxyl optionally substituted by one or several -OH or -F; -P- is as defined above; -I- is as defined above; -J- is as defined above; and -T is as defined above; d) -(CH2)a-NR6R7, wherein s is as defined above, and R6 and R7 together with the N are joined forming a five-. p£ six momborod cycle optionally containing from one to three additional heteroatoms selected from 0, S and N, and that may be fused or substituted by one or two five- or six-membered cycles optionally containing one or several heteroatoms selected from the group composed of O, S and N, all the cycles being optionally substituted by one or several radicals independently selected from . -OH, coco (=0), -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C3.-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (Ca-C4) -alkyloxy-SO^, (C1-C4) -alkyl-S020-, -NR2R3, -COHR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or ~F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and e) - (CHa)n-CO-HR6R7 wherein u is as defined above, and R6 and R7 are as defined above; with the proviso that compound of formula (I) is neither op 2- (4-benzyloxybenzoylamino) -3-phenylpropionic acid, i>W£ 2- [4- (4-methoxybenzyloxy)benzoylamino] -3-phenylpropionic acid, q^r 2- [4- (4-bromobeiX2yloxy)benzGylaiuind] -3-phenylpropionic acid In a particular embodiment of this aspect of the invention, in the compounds of formula (I), -W- is -KH-CH(E) -. In another particular embodiment -W- is -NH-CH(E)-, and -Z is a radical of the -Q-I-J-T type. In another particular embodiment -W- is -NH-CH(E)-, and -Z is a radical of the -(CH2)3-X-P-I-J-T type. In another particular embodiment -W-is -NH-CH(E)-, and -Z is a radical of the - (CH2)B-0-P-I-J-T type. In another particular embodiment -W- is -NH-CH(E)-, and -Z is a radical of the - (CH2)2-NR4-P-I-J-T type. In another particular embodiment -W- is -N (E) -CH2-CH2-. In another particular embodiment -W- is -N (S) -CH2-CH2-, and -Z is a radical of the -Q-I-J-T type. In another particular embodiment -W- is -N(E)-CH2-CH2-, and -Z is a radical of the - (CH2)S-X-P-I-J-T type. In another particular embodiment -W-is -N(E) -CH2-CH2-, and -Z is a radical of the - (CH2) g-O-P-I-J-T type. In another particular embodiment -W-is -N (E) -CH2-CH2-, and -Z is a radical of the - (CH2)2-NR4-P-I-J-T type. In another particular embodiment -A is a radical of the -0R1 type. Preferred compounds of the present invention include: (2S) -3- (4-benzyloxyphenyl) -2- [4- (4-butoxybenzyloxy)benzoylami no]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (3-bromobenzyloxy)benzoylamin o]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-chlorobenzyloxy)benzoylami no]propionic acid methyl ester; [2S) -3- (4-benzyloxyphenyl) -2- [4- (2-f luorobenzyloxy)benzoylami no]propionic acid methyl ester; [2S) -3- (4-benzyloxyphenyl) -2- [4- (3-methylbenzyloxy)benzoylami no]propionic acid methyl ester; {2S) -3-(4-benzyloxyphenyl)-2-[4-(3- trif luoromethylbenzyloxy) benzoylamino] propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester; {2S) -3- (4-benzyloxyphenyl) -2- [4- (2-methylbenzyloxy)benzoylami no]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2- trif luoromethylbenzyloxy) benzoylamino] propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (2-o- tolylethoxy) benzoylamino] propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl)-2-{4-[3-(4- propoxyphenoxy) propoxy] benzoylaminojpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (3- methoxybenzyloxy)benzoylamino]propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (2-ethoxybenzyloxy) benzoylami no]propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (4-butylbenzyloxy)benzoylamin o]propionic acid methyl ester; (25) -2- [4- (4-butylbenzyloxy)benzoylamino] -3-cyclohexylpropion ic acid methyl ester; (25) -2-{4- [2- (3-methylquinoxalin-2yloxy) ethoxy] benzoylamino} -3-phenylpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (2-pyridin-2-ylethoxy)benzoyl amino]propionic acid methyl ester; (25)-3- (4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yioxy)ethoxyjbenzoylaminojpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (pyridin-2-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (quinolin-2-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [3- (3-methylquinoxalin-2-yloxy)propoxy] benzoylaminojpropionic acid methyl ester; (25)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25) -3- (4-fluorophenyl) -2-{4- [2- (3-methylquinoxalin-2-yloxy) ethoxy] benzoylaminojpropionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (3-methylquinoxalin-2-yloxy) ethoxy]benzoylamino}propionic acid ethyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (3-methylquinoxalin-2-yloxy)ethoxy] benzoylamino }propionic acid isopropyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (3-methylquinoxalin-2-yloxy)ethoxy] benzoylamino }propionic acid propyl ester; (25) -2- (4-benzyloxybenzoylamino) -3- (4-benzyloxyphenyl)propion ic acid; (25) -2- [4- (3-benzyloxybenzyloxy) benzoylamino] -3- (4- benzyloxyphenyl)propionic acid; 3-{ (3-benzyloxybenzyl) - [4- (2- dibenzylaminoethoxy) benzoyl] amino}propionic acid; 3- ((3-benzyloxybenzyl) -{3- [2- (3-methylquinoxalin-2- yloxy) ethoxy] benzoyl}amino) propionic acid; 3-{ (3-benzyloxybenzyl) - [4- (3-benzyloxybenzyloxy)benzoyl] amino }propionic acid; 2- [4- (4-benzyloxybenzyloxy) benzoylamino] -3- (4-benzyloxyphenyl )propionic acid; (25) -2- [3- (4-benzyloxybenzyloxy)benzoylamino] -3- (4-benzyloxyphenyl) propionic acid; 3- (4-benzyloxyphenyl) -2- [3- (biphenyl-4-ylmethoxy)benzoylamino ]propionic acid; 2- [4- (3-benzyloxybenzyloxy)benzoylamino] -3- (4-bromophenyl)pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (4-butylbenzyloxy) benzoylamino]pro pionic acid; 2- [4- (4-butylbenzyloxy)benzoylamino] -3-cyclohexylpropionic acid; {.(3-benzyloxybenzyl) - [4- (4-butylbenzyloxy)benzoyl] amino}aceti c acid; 3-{ (3-benzyloxybenzyl) - [4- (4-butylbenzyloxy) benzoyl] amino}pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2-bromobenzyloxy) benzoylamino] pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2-chlorobenzyloxy) benzoylamino] pr opionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2-methylbenzyloxy)benzoylamino]pr opionic acid; 3-(4-benzyloxyphenyl)-2-[4-(3- .trifluoromethylbenzyloxy)benzoylamino]propionic acid; and 3- (4-benzyloxyphenyl) -2- [4- (2-trifluoromethylbenzyloxy) benzoylamino] propionic acid. Throughout. the description and claims, the terms (C1-C4) -alkyl, (C1-C10) -alkyl, (C1-C4) -alkoxyl, (C1-C4) -alkanoyl, (C3.-C4) -alkoxycarbonyl and (C1-C4) -alkanoyloxy shall be construed as straight or branched. Some of the compounds of formula (I) of the present invention may have one or several chiral centres. The present invention includes each one of the possible stereoisomers and mixtures thereof, particularly racemic mixtures thereof. A single enantiomer may be prepared by any of the commonly used processes, for example, by chromatographic separation of the racemic mixture on a stationary chiral phase, by resolution of the racemic mixture by fractional crystallisation techniques of the diastereomeric salts thereof, by chiral synthesis, by enzymatic resolution or by biotransformation. Pharmaceutically acceptable salts include, among others, addition salts of inorganic acids such as hydrochloric, hydrobromic, nitric, sulphuric and phosphoric, as well as addition salts of organic acids such as acetic, benzenesulphonic, benzoic, camphorsulphonic, mandelic, methanesulphonic, oxalic, succinic, f umaric, tartaric, and maleic. Likewise, an acid proton in compounds of formula (I) may be substituted by a metallic ion, for example, an alkaline metal ion, an alkaline-earth metal ion or an aluminium ion; or may be coordinated with an organic or inorganic base. An acceptable organic base includes diethylamine and triethylamine. An acceptable inorganic base includes aluminium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydroxide. There may be more than one cation or anion depending on the number of functions with charge and on the valency of cations, and anions. Some of the compounds of formula (I) of the present invention may exist in unsolvated as well as solvated forms such as, for example, hydrates. The present invention encompasses all such above-mentioned forms which are pharmaceutically active. Some of the compounds of general formula (I) may exhibit polymorphism, encompassing the present invention all the possible polymorphic forms, and mixtures thereof. Compounds of general structure (I) may be prepared following various processes perfectly known by any skill person in the field of organic synthesis. Compounds of the present invention may be synthesized using the methods described below, as- well as other processes known in the field of organic synthesis. Preferred methods include, but are not limited to, the general processes shown in the attached schemes. According to a first method (Method A) , the phenolic acid (II) is treated with the amine derivative (III) in the presence of.' a suitable coupling agent, for example the combination of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBT) , or with thionyl chloride in the presence of a tertiary base such as triethylamine (Elmore, Amino Acids Pep. Proteins 2001, 32, 107-162) . Final compounds (la) are obtained by Williamson etherif ication by displacement of a leaving group (LG) bonded to a type -Z radical with the phenol (IV) (using for example NaH, K2C03 or CS2CO3 as a base in a solvent such as DMF or acetone; (Bal-Tembe et al., Bioorg. Med. Chem. 1997, 5, 1381-1388; Cantello et al., J*. Med. Chem. 1994, 37, 3977-3985, Solar et al,, J .Org. Chem. 1966, 31, 1996-1997; EP.875510), or by Mitsunobu reaction between (IV) and a Z-OH type alcohol in the presence of, for example, diethyl azodicarboxylate (DEAD) and triphenylphosphine in tetrahydrofurane as a solvent (Mitsunobu, Synthesis 1981, 1; Hughes, Org. React. 1992, 42, 335) . An alternative strategy (Method B) involves prior alkylation of the phenolic esters (V) . After basic hydrolysis of the resulting ester, the final compounds (I) are synthesized by reaction with the amine derivative (III) . Alternatively, and only in the specific case of para substitution of the aromatic ring, the phenolic ether (VT) may be formed by aromatic nucleophilic substitution starting from the f luorinated compound (VII) . When -Z is a radical of the - (CH2) S-X-P-I-J-T type where X is 0 or S, for the alkylation of the phenol another alternative procedure may be followed (Method C) . The phenol (IV) or (V) is treated with the suitable doubl; functionalised alkylidene derivative (EP 875510) and, then, -nucleophilic substitution reaction with the desired alcoho! or thiol is carried out to obtain the compounds (Iaa) , an (lab) or the esters (Xa) and (XIa) , depending on the initia phenol. The hydrolysis of* the esters (Xa) and (XIa) and thei: subsequent reaction with the amine derivative (III) als leads to the compounds (Iaa) and (lab) . The derivatives o the sulphoxide (lac) and sulphone (lad) types are obtained by oxidation of the' corresponding thioether (lab) in the presence of oxidizing agents such as, for example, hydrogen peroxide or m-chloroperbenzoic acid. When -Z is a radical of the - (CH2) S-NR4-P-I-J-T type, the amines (Iae) may be obtained starting from the phenols (IV) or (V) following two alternative alkylation routes in every case (Method D) . In the case of phenol (IV) , the reaction with a doubly functionalised alkylidene derivative and, then, the nucleophilic substitution with the desired amines; or the etherification with the protected amine compound (XII) (as a trifluoroacetamide derivative, for example) , and subsequent functionalisation of the amine released after its deprotection (in a basic medium, or with NaBH4 (Harland and Hodge Synthesis 1984, 941-943)) yields the desired compounds. The tertiary amines of the (Iaeb) and (Iaec) types are obtained by the treatement of the compound (Iaea) with alkylating agents or by reductive alkylation, respectively. The amides (laed) are synthesized by acylation of the compound (Iaea) with the corresponding acid derivative in the presence of a tertiary amine, or by treating the secondary amine with an acid in the presence of a coupling agent such as, for example the combination of EDC and HOBT (Elmore, Amino Acids Pep. Proteins 2001, 32, 107-162) . In the case of the phenol (V), the amines (Iae) are obtained by reaction of their precursor acids (XVIb) , (XVTIb) and (XVTIIb) with the amine derivatives (III) following the methods outlined above. These acids, in turn, are obtained from the phenol (V) following an analogous process to that used in the case of the phenol (IV) . The Z-OH or Z-LG type compounds are products that have already been described. Some of them are commercially available or may be prepared following methods analogous to those used to synthesize others that are already known, such as those that are explained in detail in the following documents: EP 03062228; WO 97/31907; WO 01/00603; Daoud et al., J. Indian Chem. Soc. 1989, 66, 316-318 and Aquino, J*. . Med. Chem. 1996, 39, 562-569, some of them summarised in Scheme 1. Scheme 1 Some of the compounds (III) are commercially available products, particularly when they are a-amino acids. Others have already been described or may be synthesized following various routes, most of which have been described (March, Advanced Organic Chemistry, 1991, Ed. John Wiley & Sons; Juaristi, Enantioselective Synthesis of fi-Amino Acids, 1997, Ed. Wiley-VDH) . An approach for the preparation of the a-amino acids (W is -NH-CH(E)-) is the Sorensen synthesis (Mori, Tetrahedron 1985, 2369-2377; Scheme 2) , wherein dialkyl acyl-amide-malonate is alkylated in a basic medium and, after subsequent hydrolysis and decarboxylation, the desired oc-amino acids (Ilia) are obtained. Scheme 2 N-Substituted glycines and β-alanines (W is -N(E)-CH2- or -N(D)-CH2-CH2-) may be synthesized by the methods shown bellow, either' by reductive amination of the corresponding glycine or alanine with the suitable aldehyde (Scheme 3) using reducing agents such as NaBH4/ NaBH3CN or NaBH(AcO)3, or by nucleophilic substitution of the esters (XX) or (XXI) with the suitable amine (Scheme 4) , Scheme 3 Scheme 4 An alternative process for the synthesis of β-alanines (III) would be; the addition of the corresponding amine to the a,β-unsaturated ester of interest (Scheme 5) Scheme 5 Conversion of a compound of formula (I) into a different one involves transforming the -CO-A group into a different group. The modifications considered are: the hydrolysis of the -C00R1 substituent, wherein -Rl represents a - (C1-C4) -alkyl moiety, to yield the corresponding' carboxylic acid; the esterification of the carboxylic acids (lb) with the RIOH alcohols; and, lastly, the amination of the -COOR1 group to obtain the corresponding amides. The hydrolysis methods used are the usual ones, for example, using an alkaline hydroxide in aqueous methanol. The amination and esterification processes are those commonly used (Scheme 6) . Scheme 6 The compounds of the present invention are ligands of the PPARy and PPAR8. Therefore, they are expectedly useful for the prophylactic and/or curative treatment of a condition mediated by PPARy or PPARy / PPAR5 in an animal including a human. Thus, an aspect of the present invention relates to the use of these compounds for the preparation of a medicament for the prophylactic and/or curative treatment of a condition associated with metabolic diseases, particularly non-insulin-dependent diabetes mellitus, obesity, hypercholesterolemia, and other lipid-mediated pathologies, cardiovascular diseases associated with metabolic syndrome, inflammation and inflammatory processes in general, such as rheumatoid arthritis, atherosclerosis, psoriasis, and intestinal inflammatory disease, bone diseases, particularly osteoporosis, cancer, skin wound healing, and cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids. Therefore, this aspect of the invention is related to a method for the prophylactic and/or curative treatment of an animal, including a human, suffering from the above-mentioned pathologies, which comprises administering a therapeutically effective amount of a formula (I) compound. Another aspect of the invention relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound (I), as the active ingredient, together with appropiate amounts of pharmaceutically acceptable excipients. Preferably, the compound is administered orally, parenterally or topically. Throughout the description and claims the word "comprise" and variations of the word, such as "comprising", is not intended to exclude other additives, components, elements or steps. The disclosures in the abstract accompanying this application and in the application from which priority is claimed, are incorporated herein as reference. Additional objects, advantages and novel features of the invention will be set forth in part in the description, and in part will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The present invention will be further illustrated by the following examples. The examples are given by way of illustration only and are not to be construed as limiting. EXAMPLES H-H-NMR spectra of the compounds have been recorded using a VARIAN GEMINI-200 MHz and a VARIAN UNITY-300 MHz equipment and chemical shifts are expressed as ppm (5) from the internal reference TMS. Mass spectra have been obtained with an Agilent 1100 VL mass spectrometer. The nomenclature of the different compounds used in the present document is based on the software AUTONOM (Automatic Nomenclature) from the Beilstein Institute, which uses the IUPAC systematic nomenclature. INTERMEDIATES (IV) METHOD A: To a solution of 1 eq of the aminic derivative (III), 1 eq of the acid (II), 1.3 eq of HOBT, and 1.3 eq of EDC in tetrahydrofurane, the solution being 0.2 M in the aminic derivative, 2 eq of triethylamine were added. The reaction mixture was stirred at room temperature for 18h, and . then water and dichloromethane were added. The organic layer was separated, and the aqueous layer was extracted once with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, and filtered. The solvent was distilled off under reduced pressure and the obtained residue was purified by column chromatography. METHOD B: To a solution 0.1 M of 1 eq of the aminic derivative (III) in anhydrous dichloromethane, 2 eq of triethylamine, and 1.2 eq of the corresponding acid chloride, were added. The reaction mixture was either refluxed with stirring (secondary amines) or stirred at room temperature (primary amines) for 18h, then treated with water, twice with sodium bicarbonate and, finally, with a brine. The solvent was distilled off under reduced pressure and the obtained residue was purified by column chromatography. METHOD . C: To a solution of 1 eq of the aminic derivative (III) , and 1 eq of the corresponding acid chloride in ethyl acetate, the solution being 0.05 M in the aminic derivative, Amberlyst 21 (200 mg/mmol acid chloride) was added. The reaction mixture was either refluxed with stirring (secondary amines) or stirred at room temperature (primary amines) . Then, the resin was filtered, and the solvent was distilled off under reduced pressure. The obtained residue was purified by column chromatography. TABLE 1 INTERMEDIATES (Via) METHOD D: A suspension of 1 eg of phenol (V) , 3 eq of anhydrous potassium carbonate, and 1.3 eq of the Z-LG derivative in ethyl acetate, the suspension being aproximately 0.5 M in the phenol (V), was refluxed for 18h. Then, the suspension was allowed to cool down and the white solid was filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. METHOD E: A suspension of 1 eq of phenol (V) , 3 eq of cesium carbonate, 1.3 eq of the Z-LG derivative, and a catalythic amount of potassium iodide in anhydrous, dimethylformamide (DMF) , the suspension being 0.1 M in the phenol (V), was heatet at 80°C for 18h. Then, the suspension was allowed to cool down at room temperature, and then water' and ethyl acetate were added. The organic-layer was washed three times with brine, then dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. METHOD F: To a solution 0.1 M of 1 eq of phenol (V) in anhydrous DMF, containing a catalythic amount of potassium iodide, 1.1 eq of 60% sodium hydride in paraffin were added. The suspension was stirred at room temperature for 10 minutes and then 1.1 eq of the Z-LG derivative were added. The resulting solution was stirred at 80°C for 18h, and then allowed to cool down to room temperature. After treating with water and ethyl acetate, the organic layer was washed three times with brine, then dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by coluirm chromatography. METHOD G: To a solution of 1 eq of phenol (V), 2.2 eq of the Z-OH derivative, and 2.2 eq of triphenylphosphine in tetrahydrofurane, the solution being 0.2 M in the phenol, 2.2 eq of DEAD were added under inert atmosphere. The reaction mixture was stirred at room temperature for 18h. Then, the solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. METHOD H: To a solution 0.01 M of 1 eq of the Z-OH derivative in anhydrous DMF, 1.1 eq of 60% sodium hydride in paraffine were added slowly with stirring until bubbling was finished. Then, 1.2 eq of 4-fluorobenzoic acid methyl ester were added, and the mixture was heated at G 0 ° C for 2 Oh. The resulting solution was carefully poured over water/ice, and the mixture formed was extracted four times with ethyl acetate. The organic extracts were washed five times with brine, then dried over anhydrous magnesium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. INTERMEDIATES (VIb) METHOD J: To a solution 0.1 M of 1 eq of intermediate (VTa) in a mixture of 3:1 tetrahydrofurane: methanol, between 1.5 and 10 eq of lithium hydroxide 1 M in water were added. The resulting mixture was stirred at room temperature for 18h, then treated with HCl 1 N until pH=5-6, and extracted twice with ethyl acetate. The organic layers were dried over anhydrous ' sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. METHOD K: To a solution 0.05 M of 1 eq of intermediate (Via) in methanol, 5 eq of potassium hydroxide 1.4 M were added. The resulting solution was stirred at room temperature for 18h, then treated with HCl 1 N until acid pH, and extracted with ethyl acetate twice. The organic extracts were dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. TABLE 3 INTERMEDIATES (VI11) METHOD L: To a suspension of 1 eq of phenol (IV) , and 2 eq of cesium carbonate in anhydrous DMF, the suspension being 0.4 M in the phenol, 100 eq of LG1- (CH2) S-LG2 were added. The reaction mixture was heated • at 90°C for 18h, and then treated with water and 1,2 -dichloroethane. The organic layer was washed three times with brine, then dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. TABLE 4 INTERMEDIATE (Xa) , (XVIa) and (XIa) The following compounds were synthesized according to any of methods D, E or F, starting from intermediates (IX). TABLE 5 INTERMEDIATE (Xb) , (XVIb) and (Xlb) The following compounds were synthesized according to any of methods J or K, starting from intermediates (Xa) , (XVIa) or (XIa) . TABLE 6 INTERMEDIATE (XIV) The following compounds were synthesized according to any of methods D to G, starting from phenol (V) and amines (Xlla) or (Xllb) . TABLE 7 INTERMEDIATE (XV) The following, compounds were synthesized either according to any of methods D to F, starting either from intermediate (IX) , and the corresponding amines, or according to method M, from intermediate (XIV). METHOD M: To a solution 0.1 M of 1 eq of intermediate (XIV) (PG = trifluoroacetyl) in a mixture of tetrahydrofurane: methanol (3:1), 5 eq of lithium hydroxide 1 M in water were added. The solution was stirred until complete dissolution, then diluted with a mixture of water/ethyl acetate, and then acidified to pH=5 with HC1 1 N. The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was disolved in methanol 0.1 M and treated with 3.2 eq of thionyl chloride. The solution was refluxed for 18h, and then allowed to cool down to room temperature. The solvent was distilled off -under reduced pressure and the residual solid was broken up with hexane. TABLE 8 INTERMEDIATE (XVIIIa) The following compounds were synthesized according to any of methods A to C, starting from intermediate (XV) and the corresponding acids. TABLE 9 INTERMEDIATE (XVTIIb) The following compounds were synthesized according to methods J or K, starting from intermediate (XVTlia) . TABLE 10 EXAMPLE (la) : The compounds of formula (la) shown in Table 11 were synthesized according to any of methods D to G, starting from intermediate (IV): The compounds of formula (la) shown in Table 12 were synthesized according to any of methods A to C, starting from intermediate (VIb): The compounds of formula (Iaa) , (lab) and (lae) shown in Table 13 were synthesized according to any of methods D to F, starting from intermediate (VIII) and the corresponding alcohols, thiols or amines: TABLE 13 The compounds of formula (Iaa) y (lab) shown in Table 14 were synthesized according to methods A or C, starting from intermediate (Xb) or (Xlb) : The compounds of formula (la) shown in Table , were synthesized according to methods N or P, starting from compounds of formula (lb) METHOD N: To a solution of 1 eq of the compound of formula (lb) , 1.3 eq of HOBT and 1.3 eq of EDC in tetrahydrofurane, the solution being 0.2 M in the compound of formula (lb), 2 eq of triethylamine and 5 eq of the corresponding alcohol were added. The reaction mixture was stirred at room temperature for 18h, and then water and dichloromethane-were added. The organic layer was separated, and the aquous layer was extracted once with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, and filtered. The solvent was distilled off under reduced pressure. METHOD P: 1 Eq of the compound of formula (lb) was dissolved in the corresponding alcohol, and.2 drops of H2S04 cone, were added. The solution was stirred over night at room temperature, and the solvent was distilled off at reduced pressure. TABLE 15 EXEMPLB (lb) : METHOD Q: To . a solution 0.1 M of 1 eq of the corresponding acid chloride'in tetrahydrofurane or dioxane, an aqueous solution of 1 eq of the aminoacidic derivative, and 2 eq of sodium hydroxide was added. The resulting mixture was stirred for 18h at room temperature. Then, HCl 1 N was added dropwise until pH acid was reached, and the solution was extracted twice with ethyl acetate The combined organic layers were dried over anhydrous sodium sulfate, and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. METHOD R: To a mixture of 1 eq of acid of formula (II), 1.3 eq of HOBT and 1.3 eq of EDC, tetrahydrofurane or dioxane were added, and the resulting solution (0.2 M in the. acid of formula (II)) was stirred during 2h at room temperature. Then, an aquous solution of 1 eq of the aminoacidic derivative, and 2 eq of sodium hydroxide was added. The solution was stirred over night at room temperature. Then, HCl 1 N was added dropwise until pH acid was reached, and the solution was extracted twice with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by column chromatography. The compounds of formula (lb) shown in Table 16 were synthesized according to methods Q or R, starting from intermediates. (VTb): The compounds of formula (lb) shown in Table 17 were synthesized according to methods J or K, starting from compounds of formula (la) : EXAMPLES (Ic) and (Id) The compounds of formula (Ic) and (Id) shown in Table 18 were synthesized either according to any of methods A to C, starting from compounds of formula (lb) and the aminic derivatives HNR2R3 oR HNR2OR1: TABLB 18 Assay of binding to the PPARy2 The cDNA encoding for the open reading frame of the hPPARy2 is amplified by PCR (polymerase chain reaction) and inserted in the plasmid pGEX-4T-2. This construction (pGEX-hPPARy) is introduced into E. coli where it is overexpressed and semipurified as a fusion protein with glutathione S-transferase (GST) (Elbrecht et al., J. Biol. Cham. 1999, 274, 7913-7922) . The binding of the compounds to the GST-hPPARy2 s is determined by modifications in the method described by Lehmann et al. (J". Biol. Chem. 1995, 270, 12953-12957). The receptors (2.5 /xg) were incubated in 96-well plates in the presence or in the absence of the products with [3H]BRL-49853 (100 nM) for 3 h at 4°C, in a final volume of 200 /zL of buffer Tris-HCl 10 mM pH:8.0, containing KC1 50 mM and DTT 10 mM. Non-specific binding was determined in the presence of BRL-49853 100 /xM. The reaction mixture was transferred to a Multiscreen Durapore (Millipore) microplate containing glutathione-Sepharose 4B in every well. The reaction mixture was left to incubate with the resin during 10 min, and then centrifuged at 735 g during 2 min. To dissociate the receptor bound to the resin, reduced glutathione 10 mM is added and incubated during 10 min. The receptor was elut ed by centrifugation. Then, 800 piL of scintillation liquid were added to - the elution and the contained radioactivity was quantified by liquid scintillation spectroscopy (Microbeta Wallac, Perkin Elmer). LBD-hPPARs transactivation assay COS-7 cells were cultivated in 24-well plates and transfected with the pFACMV plasmids that encode the chimeric proteins containing the GAL4 DNA binding domain fused to the PPARy LBD. The reporter plasmid for the foregoing constructions was pFR-Luc, which contains five repetitions of the GAL4-response element in front of a promoter that controls the transcription of the luciferase gene. Lipofectamine was used as a transfection agent. The plasmids of the chimeric receptors and the reporter gene were inserted in the cells by transitory transfection in COS-7 cells in culture. When the products were added to the culture for 48 h, the luciferase activity showed the effect of the PPAR activity modulation on the transcription of the reporter construction (Wright et al., J. Biol. Chem. 2000, 275, 1873) . Cloning of human PPARoc, PPARS and PPARy2 The human PPARs cDNAs were amplified through RT-PCR* For hPPARct, RNA was obtained from HepG2 cells treated with linoleic acid; for h PPARS, KNA was obtained from untreated HepG2 cells; for hPPARy2, RNA was obtained from human white adipose tissue. Each amplified fragment was cloned into pBluescript (Stratagene®) and sequenced. One clone for each construction was selected and used as template for further subcloning and PCR amplifications. GST-fused protein construction To generate these chimeric proteins, the complete cDNA of the four human PPARs were cloned into pGEX4T2 (Amersham Biosciences) . The fragment was obtained from the pBluescript-cDNAs clones digested with endonucleases. To assess the plasmid identity and to ensure the in-phase cloning of the proteins, pGEXs constructions were sequenced. GST-hPPARy2, GST-hPPARct or GST-h PPARS fusion proteins were generated in Escherichia coli (BL21 strain DE3). Cells were cultured in LB medium to a density of A600= 1.6 odu# and induced for overexpression by addition of isopropyi~l-thio-|3-D-galactopyranoside (IPTG) -induced cultures to a final concentration of 0.5 mM. The IPTG-induced cultures were grown at room temperature o/n, before cells were harvested by centrifugation at 5000 g for 15 min. After sonication, the GST-fusion proteins were purified from the cell pellet using glutathione-Sepharose beads, following the procedure recommended by the manufacturer (Amersham Pharmacia Biotech). Excess of gluthatione was removed o/n by dyalisis at 4°C. Receptor purity was visualized by SDS-PAGE and protein content was determined by Bradford method* Receptor aliquots were stored at -80°C until use. GST-hPPARg and GST-hPPAR5 binding Using 96-well culture plates, PPARa or PPAR8 (5 μg) were diluted to a total volume of 100 μL with buffer consisting of 50 mM HEPES (pH:7.0), 50 mM KCl, 5 mM EDTA andlO mM DTT, in the presence of [3H] -GW2433 (100 and 50 nM for PPARa and PPAR5, respectively) . Nonspecific binding was estimated in parallel incubations containing 50 /xM of GW-2433. Plates were incubated for 2 h at room temperature. Free radioligand was separated from receptor-bound ligand by size exclusion chromatography using. Sephadex G-25 in 96-wells spin plates, using the Multiscreen Column Loader (Millipore). Eluted radioactivity was quantitated by liquid scintillation counting in a Microbeta counter (Perkin Elmer). In Table 19, affinity and functional activity data of some of the compounds of the present invention are- shown. CLAIMS 1. A compound of formula (I), its stereoisomers and mixtures thereof, its polymorphs and mixtures thereof, and the pharmaceutically acceptable solvates and addition salts of all of them, wherein the central benzene ring may be substituted in meta- or para-position and, -A is a radical selected from the group consisting of -OR1, -NR20R1 and -NR2R3; wherein Rl, R2 and R3 independently represent -H or - (C3.-C4) -alkyl; -W- is a biradical selected from the group: -NH-CH(E)-, and -N (D) -CH2-CH2-; wherein E is a radical of the -G-I-J-K type and D is a radical of the -G-I' -J-K type where: -G- is a bond or a - (CH2) 1-4- biradical; -I- is a biradical of a cycle selected from the following groups: a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclbhexene, all optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) -alkylsulphenyl, (C1~C4) - alky 1 sulphonyl, (C1-C4) -alkyloxy-S02- , (C1-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (C!-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; b) a five- or six-membered aromatic heterocycle containing from one to three heteroatoms selected from 0, . S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (CX-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (Cx-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; c) benzene or benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, this bicyclic system being optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02/ -CN, -F, -CI, -Br, (Cx-C4) -alkanoyl, (C1-C1 -alkoxycarbonyl, (C1-C4) - alkanoyl oxy, (C1-C4) -alkylsulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) - alky 1 sulphonyl, (C1-C4) -alkyl oxy-S02-f (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; -J- is a bond or a biradical selected from the following groups: a) - (CH2) 1-4 - alkyl idene; b) -0-, and c) -0-(C1-C4)-alkyl-; -K is a radical selected from the following groups: a) -H; b) (d-C4)-alkyl; c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkyl sulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, OXO (=0) , -CHO, -SH, -N02/ -CN, -F, -CI, -Br, (C3.-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkyl sulphonyl, (C1-C4) - alkyl oxy-S02- , (C1-C4) -alkyl-S020- , -NR2R3, -C0NR2R3, (C1-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C3.-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02- , (C1-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; -I'- is a biradical of a cycle selected from the following groups: a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all optionally substituted by one or several radicals independently selected from -OH, oxo (=o) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (CX-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; b) a five- or six-membered aromatic heterocycle containing from one to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, OXO (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C3.-C4) -alkylsulphinyl, (C1 - C4) - alkyl sulphenyl, (Cx - C4) - alkyl sulphonyl, (Cx-C4) -alkyloxy-S02-, (C!-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; c) benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkyl sulphonyl, (C1-C4) - alkyl oxy-S02 - , (C1-C4) -alkyl-S020- , -NR2R3 , -CONR2R3 , (C1-C4) -alkyl optionally substituted by one or several -OH or -F, (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F phenyl, phenoxy and benzyloxy; and d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from 0, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02/ -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (Cx-C4) -alkylsulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4)-alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; is a radical selected from the following groups: a) -Q-I-J-T wherein -Q- is a biradical -(CH2)i-3-; -I- is as defined above; -J- is as defined above; and -T is a radical selected from the following groups: a,a) -H; a.b) (C1-C4) -alkyl; a.c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, {C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; a. d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally siibstituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; a.e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -N02/ -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and a.f) a radical from a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from 0, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) - alkanoyloxy, (C1-C4) - alkyl sulphinyl, (C1-C4) -alkylsulphenyl, (Cx-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02- , (C1-C4) -alkyl-S020- , -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; b) - (CH2)S-X-P-I-J-T wherein s is 2 or 3; -X- is selected from the group consisting of -O-, -S-, -SO-, -S02- and -NR4-, being R4 a radical selected from the group: b.a) -H; b.b) (C1-C10) -alkyl; b. c) cycloalkyl, cycloalkyl-CO- , cycloalkyl- (C1-C3) -alkyl and cycloalkyl- (C1-C3) -alkanoyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=0), -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (Cx-C4) - alkyl sulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and - (C1-C4) -alkoxyl optionally substituted by one or several OH or F; b.d) phenyl, phenyl-CO-, phenyl- (C1-C3) -alkyl and phenyl- (Cx-Ca) -alkanoyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -N02, -CN, -F, -CI, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and b.e) a heterocycle, heterocycle-CO, heterocycle- (C1-C3) -alkyl and heterocycle- (C1-C3) -alkanoyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from 0, S and N, being this heterocycle optionally substituted by one or several radicals selected from -OH, oxo (=0), -CHO, -SH, -N02/ -CN, ~F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) - alkanoyl oxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-SOsO-, -NR2R3, -CONR2R3, (C3.-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; -P-is a bond or a -(CH2)i_4- biradical; -I- is as defined above; -J- is as defined above; and -T is a radical as defined above; c) - (CH2)u-CO-NR5-P-I-J-T wherein u is 1 or 2; -R5 is a radical selected from the group: c.a) -H; c-b) (C1-C1o) -alkyl; c.c) cycloalkyl and cycloalkyl- (C1-C3) -alkyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, OXO (=0), -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; c .d) phenyl and phenyl- (C1-C3) -alkyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C1) - alkyl sulphinyl, (C1-C4) - alkyl sulphenyl, (C1-C4) -alkylsulphonyl, (C1«C4) - alkyl oxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, {C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and c. e) a heterocycle and heterocycle- (C1-C3) -alkyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from 0, S and N, being this heterocyclo optionally substituted by one or several radicals selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4) -alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020-, -NR2R3, -CONR2R3, (C1-C4)-alkyl optionally substituted by one or severalseveral -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; -P- is as defined above; -I- is as defined above; -J- is as defined above; and -T is as defined above; d) - (CH2) S-NR6R7, wherein s is as defined above, and R6 and R7 together with the N are joined forming a five-, six, or seven-membered cycle optionally containing from one to three additional heteroatoms selected from O, S and N, and that may be fused or substituted by one or two f ive-or six-membered cycles optionally containing one or several heteroatoms selected from the group composed of 0, S and N, all the cycles being optionally substituted by one or several radicals independently selected from -OH, oxo (=0) , -CHO, -SH, -N02, -CN, -F, -Cl, -Br, (C1-C4)-alkanoyl, (C1-C4) -alkoxycarbonyl, (C1-C4) -alkanoyloxy, (C1-C4) -alkylsulphinyl, (C1-C4) -alkylsulphenyl, (C1-C4) -alkylsulphonyl, (C1-C4) -alkyloxy-S02-, (C1-C4) -alkyl-S020- , -NR2R3, -CONR2R3 , {C1-C4) -alkyl optionally substituted by one or several -OH or -F, and (C1-C4) -alkoxyl optionally substituted by one or several -OH or -F; and e) - (CH2)u-CO-NR6R7 wherein u is as defined above, and R6 and R7 are as defined above; with the proviso that compound of formula (I) is neither of 2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid, ;- [4-(4-methoxybenzyloxy)benzoylamino] -3-phenylpropionic acid, 2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid, , cyclopentyl- [4- (2-methylquinolin-4-ylmethoxy)benzoylamino] acetic acid methyl ester, [4-(2-methylquinolin-4-ylmethoxy) benzoylamino] (tetrahydropyran-4-yl)acetic acid methyl ester or 2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or 2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl)propionic acid. 2. The compound according to claim 1, wherein W is -NH-CH(E)-. 3. The compound according to claim 2, wherein -Z is a radical of the -Q-I-J-T type. 4. The compound according to claim 2, wherein -Z is a radical of the -(CH2)S-X-P-I-J-T type. 5. The compound according to claim 4, wherein -X- is -0-. 6. The compound according to claim 4, wherein s is 2 and -X-is -NR4-. 7. The compound of claim 1, wherein W is -N(E)-CH2-CH2-. 8. The compound according to claim 7, wherein -Z is a radical of the -Q-I-J-T type. 9. The compound according to claim 7, wherein -Z is a radical of the -(CH2)S-X-P-I-J-T type. 10. The compound according to claim 9, wherein -X- is -O-. 11. The compound according to claim 9, wherein s is 2 and -X-is -NR4-. 12. -The compound according to claim 1, wherein -A is an -OR1 type radical. 13. The compound according to claim 1 selected from the group consisting of: (2S) -3- (4-benzyloxyphenyl) -2- [4- (4-butoxybenzyloxy)benzoylami no]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (3-bromobenzyloxy)benzoylamin o]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-chlorobenzyloxy)benzoylami no]proplonic acid methyl ester,- (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-fluorobenzyloxy)benzoylami no]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (3-methylbenzyloxy)benzoylami no]propionic acid methyl ester; (2S)-3-(4-benzyloxyphenyl)-2-[4-(3- trif luoromethylbenzyloxy) benzoylamino] propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester; (2S) -3- (4-benzyloxyphenyl) -2- [4- (2-methylbenzyloxy)benzoylami no]propionic acid methyl ester; {23)-3-(4-benzyloxyphenyl)-2-[4-(2- trif luoromethylbenzyloxy) benzoylamino] propionic ■ acid methyl ester; (25) -3- (4-benzyloxyphenyl)-2-[4-(2-o- tolylethoxy)benzoylamino] propionic acid methyl ester; (25)-3- (4-benzyloxyphenyl)-2-{4-[3-(4- propoxyphenoxy) propoxy] benzoylamino}propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (3- methoxybenzyloxy)benzoylamino]propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (2-ethoxybenzyloxy)benzoylami no]propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2- [4- (4-bntylbenzyloxy) benzoyl ami n o]propionic acid methyl ester; (25) -2- [4- (4-butylbenzyloxy) benzoyl amino] -3-cyclohexylpropion ic acid methyl ester; (25)-2-{4-[2- (3-methylquinoxalin-2yloxy)ethoxy]benzoylamino}-3-phenylpropionic acid methyl estei-; (25) -3- (4-benzyloxyphenyl) -2- [4- (2-pyridin-2-ylethoxy)benzoyl amino]propionic acid methyl ester; . (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (3-methylguinoxalin-2-yloxy) ethoxy]benzoylamino}propionic acid methyl ester; (25)-3- (4-benzyloxyphenyl)-2-{4- [2- (pyridin-2-yloxy) ethoxy]benzoylamino}propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl)-2-{4- [2-(quinolin-8-yloxy) ethoxy]benzoylamino}propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl)-2-{4- [2-(quinolin-7-yloxy)ethoxy]benzoylainino}propionic acid methyl. ester; (25) -3- (4-benzyloxyphenyl)-2-{4-.[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [3- (3-methylqui^£ixa]rirn-2-yloxy) propoxy] benzoylamino}propionic acid methyl ester; (25) -3- (4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy) ethoxy]benzoylamino}propionic acid methyl ester; (25) -3- (4-fluorophenyl) -2-{4- [2- (3-methylquinoxalin-2-yloxy) ethoxy] benzoyl amino} prop ionic acid methyl ester; (25)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid ethyl ester; (25)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-raethylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester; (25) -3- (4-benzyloxyphenyl) -2-{4- [2- (3-methylquinoxalin-2-yldxy) ethoxy] benzoylamino}propionic acid propyl ester; (25) -2- (4-benzyloxybenzoylamino) -3- (4-benzyl oxyphenyl )propion ic acid; (25)-2-[4-(3-benzyloxybenzyloxy)benzoylamino] -3-(4- -benzyloxyphenyl) propionic acid; 3-{(3-benzyloxybenzyl)-[4-(2- dibenzylaminoethoxy) benzoyl] amino}propionic acid; 3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoyl}amino)propionic acid; 3-{ (3-benzyloxybenzyl) - [4- (3-benzyloxybenzyloxy)benzoyl] amino }propionic acid; 2- [4- (4-benzyloxybenzyloxy)benzoylamino] -3- (4-benzyloxyphenyl )propionic acid; (2s)-2-[3-(4-benzyloxybenzyloxy) benzoylamino]-3-(4- benzyl oxyphenyl) propionic acid; 3- (4-benzyloxyphenyl) -2-'[3- (biphenyl-4-ylmethoxy)benzoylamino ]propionic acid; 2- [4- (3-benzyloxybenzyloxy) benzoylamino] -3- (4-bromophenyl)pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (4-butylbenzyloxy)benzoylamino]pro pionic acid; 2- [4- (4-butylbenzyloxy)benzoylamino] -3-cyclohexylpropionic acid; { (3-benzyloxybenzyl) - [4- (4-butylbenzyloxy) benzoyl] amino}aceti c acid; 3-{ (3-benzyloxybenzyl) - [4- (4-butylbenzyloxy) benzoyl] amino]pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2 -bromobenzyloxy) benzoylamino] pro pionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2-chlorobenzyloxy) benzoylamino] pr opionic acid; 3- (4-benzyloxyphenyl) -2- [4- (2-methylbenzyloxy) benzoylamino] pr opionic acid; 3-(4-benzyloxyphenyl)-2-[4-(3- trifluoromethylbenzyloxy)benzoylamino]propionic acid; and 3-(4-benzyloxyphenyl)-2-[4-(2- trifluoromethylbenzyloxy)benzoylamino]propionic acid. 14. A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to any one of the claims 1 to 13 together with appropriate amounts of pharmaceutically acceptable excipients. 15. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of diseases in an animal including a human. 16. Use of the compound as defined in any one of claims- 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of PPARy mediated diseases in an animal including a human. 17. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of PPARγ / PPAR.5 mediated diseases in an animal including a human.. 18. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a condition associated with a metabolic disease in an animal including a human. 19. Use according to claim 18, wherein the metabolic disease is npn-insulin-dependent diabetes mellitus (NIDDM). 20. Use according to claim 18, wherein the metabolic disease is obesity. 21. Use according to claim 18, wherein the metabolic disease is selected from hypercholesterolaemia, and other lipid-mediated pathologies. 22. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a cardiovascular disease associated with melabolic syndrome in an animal including a human. 23. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of inflammation or an inflammatory process in general in an animal including a human. 24. Use according to claim 23/ wherein the inflammatory process is selected from rheumatoid arthritis, and atherosclerosis. 25. Use according to claim 23, wherein the inflammatory process is selected from psoriasis, and intestinal inflammatory disease. 26. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a bone disease, particularly osteoporosis, in an animal including a human. 27. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of cancer in an animal including a human. 28. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, in an animal including a human 29. Use according to any of the claims 15 to 28, wherein the medicament is administered orally,, parenterally or topically. 30. A method for the prophylactic and/or curative treatment of a condition mediated by PPARy in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 31.. A method for the prophylactic and/or curative treatment of a condition mediated by both PPARY and PPAR8 in an animal including a human, comprising administering, a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 32. The method according to any one of claims 30 or 31, wherein the administration is carried out orally, parenterally or topically. 33. A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases, comprising administering a therapeuticaly effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 34. A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a therapeuticaly effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 35. A method for the prophylactic and/or curative treatment of an animal, including a human/ suffering from inflammation or • an inflammatory process in general, comprising administering a therapeuticaly effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 36. A method for the prophylactic and/or curative treatment of an animal, including a humanr suffering from bone diseases comprising administering a therapeuticaly effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 37. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a therapeuticaly effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients. 38. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, comprising administering a therapeuticaly effective amount of a compound as defined in claim .1 together with an appropriate amount of pharmaceutically acceptable excipients.

Documents:

0121-chenp-2006-abstract.pdf

0121-chenp-2006-claims.pdf

0121-chenp-2006-correspondnece-others.pdf

0121-chenp-2006-description(complete).pdf

0121-chenp-2006-form 1.pdf

0121-chenp-2006-form 26.pdf

0121-chenp-2006-form 3.pdf

0121-chenp-2006-form 5.pdf

0121-chenp-2006-others.pdf

0121-chenp-2006-pct.pdf